Transgene

Transgene Capital Intensity

The Capital Intensity Ratio of Transgene (TNG.PA) as of Nov 19, 2026 is 693.54 %. In the previous year, Capital Intensity Ratio was 592.31 % — a change of 17.09% (higher).

Capital Intensity

693.54 %

YoY

17.09%

Last updated:

Capital Intensity Ratio of Transgene is 2024 693.54 % . Capital Intensity Ratio of Transgene was 2023 592.31 % . It decreases by 17.09% higher compared to the previous year.

The Transgene Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2017
1,352.73 EUR
Jan 1, 2018
1,533.70 EUR
Jan 1, 2019
868.51 EUR
Jan 1, 2020
914.62 EUR
Jan 1, 2021
598.55 EUR
Jan 1, 2022
664.23 EUR
Jan 1, 2023
592.31 EUR
Jan 1, 2024
693.54 EUR
The Transgene Capital Intensity history
YEARCapital IntensityYoY
693.54 %+17.09%
592.31 %-10.83%
664.23 %+10.97%
598.55 %-34.56%
914.62 %+5.31%
868.51 %-43.37%
1,533.70 %+13.38%
1,352.73 %-3.97%
1,408.68 %+33.58%
1,054.56 %-16.96%
1,269.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Capital Intensity Ratio of Transgene is 693.54 % in 2024.

Capital Intensity Ratio of Transgene changed from 592.31 % to 693.54 %, representing a 17.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Transgene since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Transgene

All Key Metrics — Transgene